OP2 DRUGS;CENTRE HOSPITALIER UNIVERSITAIRE DE BOURDEAUX;INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE);UNIVERSITE DE BORDEAUX
发明人:
Philippe DIOLEZ,Dominique DETAILLE,Frédéric MARIN,Olivier PETITJEAN
申请号：
US16368040
公开号：
US20190274997A1
申请日:
2019.03.28
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention relates to the use of compounds for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin.
